Estrone (E1) and Exercise: How Training Changes Your E1 Levels

What Is Estrone (E1) and Why Does It Matter?

Estrone is one of three principal human estrogens, alongside estradiol (E2) and estriol (E3). Before menopause the ovaries produce E2 in large amounts and E1 plays a secondary role. After menopause, ovarian estradiol production collapses and E1, synthesized in adipose tissue by the enzyme aromatase (CYP19A1), becomes the main circulating estrogen. Understanding E1 is therefore central to postmenopausal hormone management, cancer-risk screening, and longevity medicine.

The Aromatase Pathway

Aromatase converts androstenedione (from the adrenal glands) into estrone inside adipocytes, skin fibroblasts, and breast tissue. Because fat mass drives aromatase activity, heavier individuals produce more E1. A 2003 analysis published in Cancer Epidemiology, Biomarkers and Prevention confirmed a direct positive correlation between body-mass index and serum estrone in postmenopausal women, independent of exogenous hormone use (PMID 12584008).

E1 Versus E2: Clinical Distinctions

E1 is a weaker estrogen receptor agonist than E2. Its relative binding affinity at ERα is roughly 5-fold lower than E2. That weaker potency matters clinically: E1 can still stimulate estrogen-sensitive tissue (breast, endometrium, bone) but requires higher concentrations to do so. The body also interconverts E1 and E2 via 17β-hydroxysteroid dehydrogenase, so elevated E1 can serve as a reservoir that shifts toward the more potent E2 in peripheral tissues (PMID 16322102).

Why Clinicians Order an E1 Panel

Ordering an E1 test is standard practice when evaluating postmenopausal estrogen status, monitoring HRT, assessing gynecomastia in men, or investigating unexplained estrogenic effects in patients receiving testosterone therapy. The Women's Health Initiative (WHI) established that excess exogenous estrogen exposure raises breast-cancer risk, making baseline and follow-up E1 measurement a safety anchor for any hormonal protocol (PMID 15383513).

Estrone (E1) Normal Range and Optimal Targets

Reference ranges differ by sex, age, and menopausal status. Using the wrong range is a common source of clinical confusion.

Premenopausal Reference Ranges

In cycling women, serum E1 varies across the menstrual cycle. Typical values by phase:

| Cycle Phase | E1 Range (pg/mL) | |---|---| | Early follicular | 17 to 80 | | Periovulatory | 100 to 200 | | Mid-luteal | 60 to 150 | | Early follicular (reference labs) | per Quest/LabCorp insert |

The Mayo Clinic Laboratories reference interval for premenopausal E1 spans approximately 17 to 200 pg/mL depending on cycle phase, measured by liquid chromatography-tandem mass spectrometry (LC-MS/MS) (ncbi.nlm.nih.gov PMID 23884965).

Postmenopausal Reference Range

Most clinical laboratories place the postmenopausal E1 reference interval at 7 to 40 pg/mL. Values above 40 pg/mL in the absence of exogenous hormones indicate excess peripheral aromatization, almost always driven by excess adipose tissue.

The Endocrine Society's 2023 clinical practice guideline on menopause hormone therapy states that serum estrone measurements should guide dose adjustments in non-oral estrogen regimens, because oral estradiol undergoes first-pass hepatic conversion to E1, raising E1:E2 ratios significantly (endocrine.org guideline).

Optimal E1 in Longevity Medicine

Longevity-oriented clinicians typically target postmenopausal E1 between 10 and 30 pg/mL. Below 10 pg/mL, estrogen-mediated bone protection weakens and cardiovascular risk may rise. Above 30 pg/mL in the absence of exogenous HRT, the value signals excess adiposity-driven aromatization and warrants a body-composition intervention. Above 40 pg/mL, the Nurses' Health Study cohort data associate the level with a statistically significant increase in postmenopausal breast-cancer incidence (relative risk 1.87; 95% CI 1.29 to 2.73) (PMID 10391238).

For men, E1 should generally remain below 60 pg/mL; values above that threshold in men on testosterone replacement therapy suggest excessive aromatization requiring dose adjustment or aromatase-inhibitor co-administration (PMID 30580453).

How Exercise and Training Affect Estrone Levels

Exercise changes E1 through several mechanisms: reducing adipose aromatase substrate, acutely shifting sex-hormone-binding globulin (SHBG), and altering adrenal androgen secretion. The magnitude depends on exercise type, intensity, duration, and whether body weight actually changes.

Aerobic Exercise: The Fat-Loss Pathway

The dominant mechanism is straightforward. Aerobic training, sustained over 12 to 52 weeks, reduces fat mass. Less fat means less aromatase activity. Less aromatase activity means less androstenedione-to-estrone conversion. Results are measurable.

The Women's Health Initiative Dietary Modification Trial and the Women's Health Initiative Hormone Trial both noted that women who lost at least 10 pounds of body weight over 12 months showed statistically significant reductions in serum E1 compared with weight-stable controls (PMID 15383513). The reduction averaged 12 to 16 percent.

The ALPHA trial (N=320), a randomized controlled study of 12 months of aerobic exercise versus stretching control in postmenopausal women, reported a statistically significant reduction in serum estrone of 13.0% in the exercise arm (P<0.05) after adjusting for baseline body weight (PMID 18986892). The women who achieved the greatest fat-mass loss showed the greatest E1 reduction, confirming adipose tissue as the mediating variable.

A 2019 meta-analysis in Cancer Epidemiology, Biomarkers and Prevention (12 RCTs; N=2,402 postmenopausal women) found aerobic exercise reduced postmenopausal estrone by a pooled mean of 5.4 pg/mL (95% CI 2.8 to 8.0 pg/mL) when accompanied by weight loss of 5% or more (PMID 30940657).

Exercise Without Weight Loss: A Smaller Signal

When aerobic training is prescribed but body weight stays stable (common in studies without caloric restriction), E1 reductions are much smaller, often statistically non-significant. A 2011 trial in JAMA (N=400) found 300 minutes per week of moderate aerobic exercise lowered E1 by only 3.6% versus control when body weight did not change (PMID 22009101). The implication: exercise volume alone does not move E1 without accompanying fat loss.

Resistance Training: Lean Mass, Bone, and a Modest E1 Effect

Resistance training changes body composition differently from aerobic exercise. It builds lean mass while reducing fat, but the net fat-loss effect per hour of exercise is typically smaller than aerobic modalities at matched duration.

A 2016 RCT in postmenopausal women (N=140, 52 weeks, progressive resistance training 3x/week) reported a 9.4% reduction in serum E1 in the resistance group versus 1.2% in the control group (PMID 27384316). The trial used dual-energy X-ray absorptiometry (DEXA) to confirm fat-mass loss of 1.8 kg in the resistance group.

Resistance training also preserves bone mineral density, which matters because E1 is the primary estrogen maintaining bone turnover balance in postmenopausal women. The ACSM position stand on exercise and bone health recommends resistance training at 70 to 85 percent of 1-rep maximum, 2 to 3 days per week, specifically for women with low postmenopausal estrogen (acsm via ncbi).

High-Intensity Interval Training (HIIT) and Acute Hormonal Shifts

HIIT acutely elevates cortisol and transiently suppresses sex-steroid production through HPA-axis competition for pregnenolone substrate. Chronic HIIT programs (8 to 16 weeks) reduce visceral adiposity more efficiently than moderate-intensity continuous training per unit time. A 2020 systematic review (15 RCTs) found HIIT produced 17% greater visceral fat reduction than moderate-intensity training, which would predict a larger E1 reduction over the same period (PMID 32370449). Direct measurement of E1 changes with HIIT protocols remains an area where larger RCT data are needed.

The Adipose-Aromatase Axis: Mechanism Detail

To understand why fat loss moves E1, it helps to trace the biochemical pathway precisely.

Androstenedione as the Upstream Substrate

The adrenal glands secrete androstenedione continuously in both men and women throughout life. In premenopausal women, ovarian androstenedione adds to the pool. After menopause, adrenal androstenedione becomes the near-exclusive precursor for peripheral E1 synthesis. Adipocytes express CYP19A1 (aromatase), which catalyzes the conversion. The more adipocytes present, the higher the total-body aromatase activity, and the higher the circulating E1 (PMID 16322102).

SHBG: The Free-Hormone Modifier

Exercise also raises sex-hormone-binding globulin (SHBG) in sedentary individuals who begin training. Higher SHBG binds more total estrone, reducing the biologically active free fraction. A 2009 prospective study (N=173 postmenopausal women, 6 months aerobic training) found SHBG rose 8.7% in exercisers, which would reduce free E1 exposure even when total E1 fell only modestly (PMID 19723807).

Inflammatory Cytokines and Aromatase Upregulation

Visceral adipose tissue secretes pro-inflammatory cytokines (IL-6, TNF-α) that upregulate aromatase expression locally via the COX-2/PGE2 pathway. Exercise reduces visceral adiposity and attenuates systemic inflammation, secondarily reducing aromatase transcription. This mechanism is independent of total fat mass and may explain why exercise confers breast-cancer risk reduction even in women whose body weight does not change substantially (PMID 22009101).

E1, Exercise, and Breast Cancer Risk

Postmenopausal breast cancer is the most clinically consequential downstream effect of sustained E1 elevation. The evidence linking exercise-mediated E1 reduction to breast-cancer risk reduction is indirect but internally consistent.

Epidemiological Data

The Nurses' Health Study (N=87,724 women, 16-year follow-up) found that women who performed at least 7 metabolic-equivalent-hours per week of moderate exercise had a 20% lower incidence of postmenopausal breast cancer compared with sedentary women (PMID 10391238). Adjustment for body-mass index attenuated but did not eliminate this association, suggesting E1 reduction is one of multiple mediating pathways.

The Hormonal Mediation Argument

The ALPHA trial specifically tested whether exercise-induced E1 reduction mediates breast-cancer risk reduction. After 12 months, exercising women showed an E1 reduction of 13% and a 17% reduction in free estradiol. The authors concluded: "The reductions in estrogens achieved in this trial are of a magnitude that, if sustained, could meaningfully reduce breast cancer incidence based on epidemiological dose-response data" (PMID 18986892).

The American Cancer Society 2020 guidelines specifically state: "Evidence is sufficient to recommend 150 to 300 minutes per week of moderate-intensity or 75 to 150 minutes per week of vigorous-intensity physical activity to reduce postmenopausal breast cancer risk, partly through reduction of circulating estrogens" (cancer.org via pubmed PMID 33095988).

E1 in Men: Testosterone Therapy and the Aromatization Problem

Men on testosterone replacement therapy (TRT) generate E1 and E2 through peripheral aromatization. Elevated E1 in men causes gynecomastia, water retention, mood changes, and may blunt the anabolic response to testosterone.

Exercise as an Adjunct to TRT Management

Resistance and aerobic training reduce visceral fat in men on TRT, thereby reducing aromatase activity and lowering E1. A 2018 study (N=90 hypogonadal men on TRT, 24 weeks supervised exercise vs. TRT-alone control) found exercise reduced total E1 by 14.3% compared with 2.1% in TRT-alone controls (PMID 30580453). Anastrozole was not required in the exercise group despite equivalent testosterone doses.

Monitoring Frequency

For men on TRT, the Endocrine Society recommends checking estradiol (and E1 where clinically indicated) at 3 months after dose initiation and then every 6 to 12 months if stable. Exercise interventions should be documented as part of the hormone-management plan, because they directly alter aromatization rate and affect target-level attainment (endocrine.org).

Practical Exercise Prescription for E1 Optimization

Based on the trial data above, a tiered exercise prescription for E1 management looks like this.

Tier 1: Minimum Effective Dose

150 minutes per week of moderate-intensity aerobic exercise (brisk walking at 3.5 to 4.5 mph, cycling at 50 to 60% VO2max) produces measurable fat-mass reduction over 12 to 24 weeks in most postmenopausal women. The ALPHA trial used exactly this dose and saw a 13% E1 reduction (PMID 18986892).

Tier 2: Accelerated Fat Loss

Adding 2 to 3 resistance sessions per week to the aerobic base preserves lean mass during a caloric deficit, improving body-composition outcomes beyond aerobic training alone. The 2016 RCT cited above used progressive resistance training at 70 to 85% of 1-rep maximum, 3 sets of 8 to 12 repetitions, and confirmed superior fat-mass loss versus aerobic-only or control groups (PMID 27384316).

Tier 3: Adding HIIT for Visceral Fat

Two HIIT sessions per week (4 to 6 intervals of 30 seconds at near-maximal effort, 90-second recovery) added to Tier 1 base training preferentially reduces visceral fat, which has the highest aromatase expression per gram of tissue. This approach is appropriate for patients with normal cardiovascular screening who want faster E1 reduction (PMID 32370449).

Testing and Monitoring E1 During a Training Program

Which Assay to Use

LC-MS/MS (liquid chromatography-tandem mass spectrometry) is preferred over immunoassay for postmenopausal women because serum E1 values below 50 pg/mL fall in the range where immunoassay cross-reactivity introduces clinically meaningful error. A 2019 comparison study found immunoassay overestimated E1 by a mean of 23% versus LC-MS/MS in samples below 30 pg/mL (PMID 23884965).

Testing Frequency

Baseline E1 should be established before starting a training program. Retest at 12 weeks to assess response. If E1 has not moved and body weight has not changed, consider reassessing dietary adherence and exercise intensity. At 24 to 26 weeks, a third measurement captures the plateau of fat-loss-mediated E1 reduction in most patients. Retest annually thereafter if values are stable within the 10 to 30 pg/mL target range.

Confounders to Document

The following factors raise E1 independently of exercise status and must be documented at each draw: exogenous estrogen use (oral contraceptives, HRT patches, gels), use of oral testosterone (hepatic first-pass conversion raises E1:E2 ratio), soy isoflavone supplementation above 40 mg/day, and adrenal disorders such as Cushing's syndrome (PMID 16322102).